Navigation Links
VIVUS to Present at Four Upcoming Healthcare Conferences
Date:9/1/2009

MOUNTAIN VIEW, Calif., Sept. 1 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, Chief Financial Officer, will present an overview of the company at four healthcare investment conferences during the month of September.

The conference presentation schedule is as follows:

        Rodman & Renshaw Annual Global Investment Conference
        September 10, 2009 at 10:50 a.m. ET
        The New York Palace Hotel, New York, NY

        Thomas Weisel Partners Healthcare Conference
        September 11, 2009 at 11:30 a.m. ET
        The Four Seasons Hotel, Boston, MA

        BioCentury's NewsMakers in the Biotech Industry Conference
        September 16, 2009 at 3:30 p.m. ET
        Millennium Broadway Hotel & Conference Center, New York, NY

        UBS Global Life Sciences Conference
        September 21, 2009 at 3:30 p.m. ET
        Grand Hyatt, New York, NY

A live audio webcast and 30-day archive of the presentations will be available on VIVUS' website at http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:
    Timothy E. Morris
    Chief Financial Officer
    VIVUS, Inc.
    +1-650-934-5200,

    Brian Korb
    Investor Relations
    The Trout Group,
    +1-646-378-2923

    Sheryl Seapy
    Media Relations
    Pure Communications, Inc.
    +1-949-608-0841


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. VIVUS to Present at the Needham and Company Life Sciences Conference
3. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
4. VIVUS Reports First Quarter 2009 Financial Results and Highlights
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
6. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
7. Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. Beckman Coulter to Present at Upcoming Healthcare Conferences
10. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
11. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... WonderWorks, Myrtle Beach’s science focused amusement ... of deep space exploration and inspire space enthusiasts. The exhibit features interactive exhibits ... guest appearance by former Shuttle Astronaut Don Thomas. , The intergalactic weekend kicks ...
(Date:4/26/2017)... ... April 26, 2017 , ... As the call ... healthcare industry stakeholders, the discussion surrounding the topic will continue at WEDI 2017- ... in Los Angeles, Calif. Hosted by the Workgroup for Electronic Data Interchange (WEDI), ...
(Date:4/25/2017)... R.I. , April 25, 2017 ... Inc. ("EpiVax") has licensed its novel immune-modulating technology to ... autoimmune disease and allergy. Tregitopes, pronounced ... in human immunoglobulin by EpiVax CEO Annie ... Similar to intravenous immunoglobulin G, an autoimmune disease ...
(Date:4/24/2017)... , April 24, 2017  Dante Labs announced today the ... EUR 850 (ca. $900). While American individuals have been able ... time Europeans can access WGS below EUR 1,000. ... to leveraging genetic information to make informed decisions about disease ... ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):